Cipher Pharmaceuticals Inc
TSX:CPH
Operating Margin
Cipher Pharmaceuticals Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CA |
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
318.2m CAD |
18%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.3B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
395.4B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
203.3B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
177.2B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
158.7B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
199.6B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
137.9B USD |
27%
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Cipher Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 18.4%.
You don't have any saved screeners yet